Has Astellas Pharma (TSE:4503) Run Too Far After Its 61% One Year Share Price Jump? [Yahoo! Finance]
ASTELLAS PHARMA UNSP/ADR (ALPMY)
NASDAQ:AMEX Investor Relations:
astellas.com/jp/en/investors
Company Research
Source: Yahoo! Finance
If you are wondering whether Astellas Pharma's current share price still offers value, this article walks through what the numbers are saying about the stock. The shares last closed at ¥2,302, with returns of 4.0% over 7 days, 8.3% over 30 days, 8.1% year to date and 60.7% over the past year, which may have shifted how some investors view its risk and return profile. Recent news coverage has highlighted Astellas Pharma in the context of broader interest in large pharmaceutical names in Japan, as investors pay closer attention to established drug pipelines and balance sheets. This has kept the company on the radar of investors who track the sector and are reassessing where it might fit in their portfolios. Astellas Pharma currently has a valuation score of 2 out of 6. Next, we will look at what different valuation approaches say about that score, before finishing with a way to put all these methods together into a clearer picture of value. Astellas Pharma scores just 2/6 on ou
Show less
Read more
Impact Snapshot
Event Time:
ALPMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALPMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALPMY alerts
High impacting ASTELLAS PHARMA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
ALPMY
News
- VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses [Yahoo! Finance]Yahoo! Finance
- VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc AnalysesPR Newswire
- Astellas to Present at 44th Annual J.P. Morgan Healthcare ConferencePR Newswire
- How Attractive Is Astellas Pharma After a 44.1% Surge and Mixed Valuation Signals? [Yahoo! Finance]Yahoo! Finance
- Positive Phase 3 PADCEV–Keytruda Bladder Cancer Data Could Be A Game Changer For Astellas Pharma (TSE:4503) [Yahoo! Finance]Yahoo! Finance